

E-Rare Joint Transnational Call for Proposals 2014

"Development of Innovative Therapeutic Approaches for Rare Diseases"

Submission deadline for pre-proposals: January 30, 2014

Please find the links to pre-proposal template, electronic proposal submission, guidelines for applicants and further information on the website

www.e-rare.eu

or contact the joint call secretariat:

Ignacio Baanante
E-rare2sec@isciii.es
(+34) 918222576



Call text

1. MOTIVATION

There are at least 6.000 to 7.000 distinct rare diseases, the great majority being of genetic origin. Although individually rare, taken together rare diseases affect at least 26-30 million people in Europe. Moreover, they represent a major issue in health care: a large number of these diseases lead to a significant decrease of life expectancy and most of them cause chronic illnesses with a large impact on quality of life and the health care system.

Therefore, research on rare diseases is needed to provide knowledge for prevention, diagnosis and better care of patients. Yet, research is hampered by lack of resources at several levels: (1) Few scientists work on one specific disease, (2) There are few patients per disease and they are scattered over a large geographic area, causing difficulties to gather the necessary cohorts, (3) Existing databases and material collections are usually local, small, and not accessible or standardised, (4) Diseases often have complex clinical phenotypes and require interdisciplinary cooperation for research, hence, interdisciplinary approaches to treatment.

The specificities of rare diseases - limited number of patients, scarcity of relevant knowledge and expertise, and fragmentation of research - single them out as a distinctive domain of very high European added-value. Rare diseases are therefore a prime example of a research area that can strongly benefit from collaboration/coordination on a transnational scale.

In this context, the ERA-Net “E-Rare” for research programmes on rare diseases has been extended to a second phase “E-Rare-2” (2010-2014) to further help in coordinating the research efforts of European countries in the field of rare diseases.

The following parties,

- The Austrian Science Fund (FWF), Austria
- The Research Foundation - Flanders (FWO), Belgium, Flanders
- The Canadian Institutes of Health Research – Institute of Genetics (CIHR-IG), Canada
- Le Fonds de recherche du Québec-Santé (FRQS), Québec (Canada)
- The French National Research Agency (ANR), France
- The Federal Ministry of Education and Research (BMBF), Germany
- The Hungarian Scientific Research Fund (OTKA), Hungary
- The Chief Scientist Office of the Ministry of Health (CSO-MOH), Israel
- The Italian Ministry of Health (MoH), Italy
- The Latvian Academy of Sciences (LAS), Latvia
- The National Centre for Research and Development (NCBR), Poland
- The Foundation for Science and Technology (FCT), Portugal
- The Executive Agency for Higher Education, Research, Development and Innovation Funding (UEFISCDI), Romania
- The National Institute of Health Carlos III (ISCIII), Spain
- The Swiss National Science Foundation (SNSF), Switzerland
- The Netherlands Organization for Health Research and Development (ZonMw), The Netherlands
- The Scientific and Technological Research Council of Turkey (TÜBİTAK), Turkey

have decided to open the sixth E-Rare joint transnational call (JTC 2014) for funding multilateral research projects for promoting the development of innovative therapeutic

approaches on rare diseases. The call is being opened simultaneously by the partners in their respective countries.

2. AIM OF THE CALL

The aim of the E-Rare Joint Transnational Calls (JTCs) is to enable scientists in different countries to build an effective collaboration on a common interdisciplinary research project based on complementarities and sharing of expertise, with a clear translational research approach.

The specific objective of this call is to promote the development of innovative therapeutic approaches for rare diseases. In order to achieve this goal, the necessary expertise and resources should be brought together from academia, clinical/public health sector and private companies.

Projects shall involve a group of rare diseases or a single rare disease following the European definition (a seriously debilitating and/or life-threatening disease affecting not more than 5 in 10.000 people). **Rare infectious diseases, rare cancers and rare adverse drug events in treatments of common diseases are excluded from the scope of the call.**

The research projects have to focus on the pre-clinical development of therapeutic approaches in suitable existing animal or cell models.

Therapeutic approaches can include (but are not limited to):

- Cell-based therapy (e.g. somatic cell therapy, cell-based regenerative medicine, tissue engineering, therapies based on combinations of cells with scaffolds or substrates, etc.)
- Gene therapy (e.g. transfer of nucleic acids for therapeutic purposes including DNA, RNA, oligonucleotides etc.)
- Pharmacological therapy (e.g. use of chemicals or biopharmaceuticals including repurposing approaches, high throughput screening of molecules, etc.)

The following approaches and topics are **excluded** from the scope of the call:

- Development of new cell or animal models. The relevant cell or animal models do already need to be established for the purpose of the project
- Interventional clinical trials or any projects enrolling patients
- Therapeutic approaches concerning rare infectious diseases, rare cancers and rare adverse drug events in treatments of common diseases
- Surgery or radiation therapies

Project proposals must clearly demonstrate the potential health impact as well as the added-value of transnational collaboration: sharing of resources (cell and animal models, compounds, databases, etc.), sharing of specific know-how and/or innovative technologies, etc.

The aim of the call is in compliance with the goals set by the International Rare Diseases Research Consortium (IRDiRC) which was launched in April 2011 to foster international

collaboration in rare diseases research. For more information see IRDiRC website: <http://www.irdirc.org/>

3. MANAGEMENT BOARDS

Two boards, the Call Steering Committee (**CSC**) and the Scientific Evaluation Committee (**SEC**), will manage the evaluation process of the call with support of the Joint Call Secretariat (**JCS**) (set up at ISCIII, Spain). The process includes the evaluation procedure of pre- and full-proposals and the final selection and award of research projects.

- **The Call Steering Committee (CSC)** is composed of a single representative from each country/region funding organisation. The CSC will supervise the progress of the call and the evaluation of proposals. The CSC will make the final funding recommendation to the national/regional funding organisations on the proposals to be funded, based on the final ranking list provided by the SEC. All decisions concerning the call procedures will be taken by the CSC.
- **The Scientific Evaluation Committee (SEC)** is a panel of internationally recognised scientific experts responsible for the evaluation of submitted proposals. SEC members will not submit or participate in proposals within this call, and must sign a confidentiality form and a statement to confirm that they do not have any conflicts of interest. The SEC will nominate external peer reviewers.

4. APPLICATION

4.1. Funding recipients/Eligibility

Joint research proposals may be submitted by applicants belonging to one of the following categories (according to country/regional regulations):

- academia (research teams working in universities, other higher education institutions or research institutes)
- clinical/public health sector (research teams working in hospitals/public health and/or other health care settings and health organisations)
- enterprise (all sizes of private companies). Participation of small and medium-size enterprises (SMEs) is encouraged when allowed by national/regional regulations

➤ Please note that the inclusion of a non-eligible partner in a proposal **leads to the rejection of the entire proposal without further review**. Whilst applications will be submitted jointly by research groups from several countries, individual groups will be funded by the individual funding organisation of their country/region that is participating in the E-Rare-2 JTC 2014. The applications are therefore subject to **eligibility criteria of individual funding organisations**. Applicants are strongly advised to contact their corresponding national/regional representative and confirm eligibility with their respective funding organisations in advance of submitting an application (see national/regional contact details and Annex).

Only transnational research projects will be funded. Each consortium submitting a proposal must involve a **minimum of three** and a **maximum of six eligible research groups** from at

least three different countries participating to the call. Not more than two eligible research groups from the same partner country participating in the call will be accepted. Groups that secure their own funding may join consortia.

The consortium coordinator, as well as a minimum of 50% of all research groups, must be eligible to receive funding from the funding organisations participating in the call.

Research groups from countries whose funding organisations are not partners in this E-Rare-2 call may participate in projects if they secure their own funding.

It must be clearly stated in the proposal by all research groups that secure their own funding how these funds are already secured, and if not, how they plan to obtain funding in advance. Documentation of the availability of funds will be required before October 1st, 2014.

Each transnational collaborative project should represent the critical mass to achieve ambitious scientific goals and should clearly demonstrate an added value from working together. Industry is explicitly invited for its active participation in order to ensure an efficient transfer of pre-clinical results into application.

Each transnational proposal must nominate a project consortium coordinator among the project partner principal investigators. The coordinator must be a project partner from an E-Rare-2 JTC 2014 funding country/region. The project coordinator will represent the consortium externally and towards the JCS and CSC, and will be responsible for its internal scientific management (such as controlling, reporting, intellectual property rights issues and contact with the JCS). Each project partner will be represented by one (and only one) principal investigator. Within a joint proposal, each project partner principal investigator will be the contact person for the relevant country/regional funding organisation.

The duration of the projects can be up to 3 years. Nevertheless, a partner can receive funding for less than 3 years according to E-Rare-2 JTC 2014 funding organisations eligibility criteria and regulations.

4.2. Submission of joint proposals

There will be a **two-stage submission procedure for joint applications**: pre-proposals and full proposals. In both cases, one joint proposal document (in English) shall be prepared by the partners of a joint transnational proposal, and must be submitted to the JCS by uploading it on the electronic submission system (<https://www.pt-it.de/ptoutline/ERARE14>) by one spokesperson, the coordinator. Only pre-proposals and full proposals templates duly completed following the “Guidelines for applicants” will be accepted.

Joint **pre-proposals** (in English) must be received by the JCS in an electronic version no later than **30th January 2014 at 20:00 UTC**.

The decision on selection of applications for invitation to full proposal will be communicated by mid of April 2014.

Please note that **joint full proposals will be accepted only from those applicants explicitly invited by the JCS to submit them**. Full proposals (in English) must be received by the JCS in an electronic version no later than **26th May 2014 at 20:00 UTC**.

The information given in the pre-proposal is binding. Thus, any fundamental changes between the pre- and full proposals, e.g. composition of the consortia, objectives of the

project, must be communicated to the JCS with detailed justification and will only be allowed by the CSC under exceptional circumstances.

The selection on full proposals will be communicated to applicants as soon as possible and before the end of October 2014.

Further information on how to submit pre-proposals and full proposals electronically will be made available through the E-Rare website (www.e-rare.eu) and in the "Guidelines for applicants". The forms that have to be used for submission of pre-proposals and full proposals are available on the E-Rare website. Applicants should take note of individual national/regional rules, and should contact their national/regional contact person for any questions (see "contact information" section).

For applicants from some countries/regions it might be necessary to submit the proposals and/or other information directly to the country/regional funding organisations. Therefore, applicants are strongly advised to check their national/regional funding organisations for more details (see country/regional contact details and "Guidelines for applicants").

4.3. Further information

If you need additional information, please contact the JCS or your national/regional funding organisation representative (see contact information below). For further details please refer to the "Guidelines for applicants" or www.e-rare.eu.

5. EVALUATION

5.1. Evaluation criteria

Pre-proposals and full proposals will be assessed according to specific evaluation criteria (see below), using a common evaluation form. A scoring system from 0 to 5 will be used to evaluate the proposal's performance with respect to the different evaluation criteria.

Scoring system:

0: fails or missing/incomplete information; **1:** poor; **2:** fair; **3:** good; **4:** very good; **5:** excellent

Evaluation criteria:

- Scientific and technological quality of the proposal (innovative potential, adequate methodology)
- Feasibility of the project (adequate requested resources, time schedule)
- International competitiveness of participating research groups in the field(s) of the proposal (previous work in the field, expertise of the research groups)
- Level of collaborative interaction between the groups and added value of the transnational consortium
- Potential of the expected results for future clinical, public health and/or other socio-economic health relevant applications (impact)

5.2. Eligibility check of pre-proposals and first step peer review

5.2.1. Eligibility check

The JCS will check all pre-proposals to ensure that they meet the call's formal criteria (date of submission; number and country distribution of participating research groups; inclusion of all necessary information in English, page length of each section). The JCS will forward the proposals to the CSC members who will perform a check for compliance to country/region rules.

Please note that proposals not meeting the formal criteria or the national/regional eligibility criteria and requirements **will be declined without further review.**

5.2.2. Peer review of pre-proposals

Proposals passing the eligibility check (call secretariat and country/region) will be forwarded to the SEC members for a first evaluation (see evaluation criteria above). The SEC will meet to establish a ranking of the proposals. The CSC will meet to decide which proposals will be accepted for the full proposal submission based on the SEC recommendations.

5.3. Evaluation of full proposals with right to reply (rebuttal stage)

5.3.1. Formal criteria check

The JCS will check the full proposals to ensure that they meet the call's formal criteria and have not changed substantially from the respective pre-proposals before sending them to the external reviewers.

5.3.2. External reviewer's evaluation

Each proposal will be allocated to at least two external reviewers who fit the profile of the application.

5.3.3. Rebuttal stage

Before the SEC members see the reviews from external reviewers, each project coordinator will be provided with the opportunity of studying the assessments and commenting on the arguments and evaluations of the reviewers, which remain anonymous. This stage allows applicants to comment on factual errors or misunderstandings that may have been committed by the external reviewers while assessing their proposal and to reply to reviewers' questions. However, issues which are not related with reviewers' comments or questions cannot be addressed and the work plan cannot be modified at this stage.

The applicants will have up to one week (between first and second week of July) for this **optional** response to the reviewers' comments.

5.3.4. SEC evaluation

The JCS will send full proposals, reviews and rebuttals to the SEC members. The SEC will meet to discuss each proposal and, after consideration of the evaluation criteria, external reviews, rebuttals and their own discussions, the SEC will make a classification of the proposals and rank proposals recommended for funding.

5.4. Funding decision

Based on the proposals' classification established by the SEC and on available funding the CSC will suggest the projects to be funded to the national/regional funding organisations.

Based on these recommendations, final decisions will be made by the national/regional funding organisations and will be subject to budgetary considerations.

The Joint Call Secretariat will communicate to all project coordinators the final decisions together with the review from the SEC.

6. FINANCIAL AND LEGAL ISSUES

6.1. Funding model

The E-Rare-2 JTC 2014 Funding Partners have agreed to launch a joint call using the “virtual common pot funding mode. This means that national/regional funding will be made available through national/regional funding organisations according to national/regional funding regulations. Each country/region funds only its national/regional component of the transnational research project. The funding rate within the call will be variable up to a maximum of 100% of the funds requested, according to national/regional rules. Prior to submitting a proposal, applicants should verify their eligibility and the rate of financial support with their national/regional funding organisation, and are recommended to contact their national/regional contact person (see national/regional contact details).

Funding is granted for a maximum of three years according to national regulations. Eligible costs may vary according to the corresponding national/regional funding organisation regulations. Each group is subject to the rules and regulations of their respective national/regional funding organisation.

6.2. Funding contracts

Each project includes several consortium members called research partners and one project coordinator. Each research partner (including the project coordinator) will have a separate funding contract/letter of grant according to national/regional regulations with the appropriate national/regional funding institutions.

Changes to the composition of research consortia or in budget cannot occur during the contract/letter of grant, unless there is a good justification. Any minor changes have to be well justified and the relevant funding organisations will decide upon the proper action to be taken. However, in case of major changes, an independent expert can be consulted to help with the final decision of the funding organisations. The research partners shall inform the JCS and the funding bodies of that project of any event that might affect the implementation of the project.

6.3. Research consortium agreement and ownership of intellectual property rights

The project consortium partners must sign a consortium agreement (CA) for cooperation addressing the issues given in “Guidelines for applicants” on consortium agreements (available on the E-Rare-2 website). The research consortium is strongly encouraged to sign this CA before the official project start date, and in any case the CA has to be signed no later than six months after the official project start date. Upon request, this consortium agreement must be made available to the concerned E-Rare-2 JTC 2014 funding organisations. Please note that for some agencies the signature of the CA is mandatory before the project starts (see country/regional details in the "Guidelines for applicants").

Results and new Intellectual Property Rights (IPR) resulting from projects funded through the E-Rare-2 Joint Transnational Call will be owned by the researchers' organisations according to national rules on IPR. If several participants have jointly carried out work generating new IPR, they shall agree amongst themselves (consortium agreement) as to the allocation of ownership of IPR, taking into account their contributions to the creation of those IPR as well as the European guidelines on IPR issues.

The results of the research project and IPR created should be actively exploited and made available for use, whether for commercial gain or not, in order for public benefit to be obtained from the knowledge created.

The funding partners shall have the right to use documents, information and results submitted by the research partners and/or to use the information and results for their own purposes, provided that the owner's rights are kept and taking care to specify their origin.

6.4. IRDiRC policies and guidelines

The project partners are expected to follow IRDiRC policies and guidelines and to participate in IRDiRC working groups. For more information see <http://www.irdirc.org/>.

7. RESPONSIBILITIES, REPORTING REQUIREMENTS AND DISSEMINATION

The coordinators of all the funded projects must submit **brief annual scientific project reports and a final scientific project report** (within six months of the end of the project) to the JCS. All reports must be in English and use a common report form that will be provided. The research partners are jointly responsible for delivery of the reports, and the JCS will only accept reports delivered on behalf of the consortium, via the project coordinator.

If required, each participant should submit financial and scientific reports to their **national/regional funding organisations**, according to national/regional regulations. The progress and final results of each individual contract/letter of grant will be monitored by the respective national/regional funding organisations.

Funding recipients must ensure that all outcomes (publications, etc.) of transnational E-Rare-2 projects include a proper acknowledgement of ERA-Net E-Rare-2 and the respective national/regional funding partner organisations.

The coordinators and/or national group leaders might be asked to present the results of their projects at an **intermediate and/or a final status symposium** organized by the JCS. They should foresee an appropriate travel budget in the application to participate in such an event.

8. CONTACT AND FURTHER INFORMATION

The JCS is set up at ISCIII (The National Institute of Health Carlos III, Spain) to assist the CSC and the national/regional funding bodies during the implementation of the call and the follow-up phase until the funded research projects have ended. The JCS will be responsible for the administrative management of the call. It will be the primary point of contact referring to the call procedures between the research consortia, the funding organisations (CSC) and the peer reviewers. The project coordinator will be the person contacted by the JCS during the application procedure, so he/she must forward this information to the other participants.

Further information on the E-Rare-2 Project, the Call and the follow-up is available at the E-Rare-2 website (www.e-rare.eu). It is advised to contact the national/regional contact person for any questions regarding the Call (please see national/regional contact details below).

ANNEX I. National/regional contact details

Country/Region	Institution	Website	National contact
Austria	FWF	www.fwf.ac.at	Stephanie Resch Phone: +43(1) 505 67 40-8201 stephanie.resch@fwf.ac.at Iris Fortmann Phone: +43(1) 505 67 40-8211 iris.fortmann@fwf.ac.at
Belgium (Flanders)	FWO	www.fwo.be	Olivier Boehme Phone: 00 32 2 550 15 45 eragnet@fwo.be
Canada	CIHR-IG	http://www.cihr-irsc.gc.ca	Marilyn Desrosiers Deputy Director, Strategic Program Design and Analytics, CIHR Phone: 613-954-6242 marilyn.desrosiers@cihr-irsc.gc.ca
Canada (Québec)	FRQS	http://www.frsq.gouv.qc.ca/	Fonds de recherche du Québec-Santé (FRQS) Karine Genest (514) 873-2114, ext 1275 Karine.genest@frq.gouv.qc.ca Anne-Cécile Desfaits (514) 873-2114, ext 1368 annececile.desfaits@frq.gouv.qc.ca
France	ANR	www.agence-nationale-recherche.fr	Natalia Martín + (33) (0) 1 73 54 81 33 natalia.martin@agencerecherche.fr Health and Biology Department Agence Nationale de la Recherche-ANR- 7 rue de Watt- 75013 Paris, France
Germany	BMBF/PT-DLR	www.gesundheitsforschung-bmbf.de	Michaela Girgenrath (++49) (228) 3821-1775 Michaela.girgenrath@dlr.de Ralph Schuster (++49) (228) 3821-1233 Ralph.Schuster@dlr.de Peter Buch (++49) (228) 3821-1129 Peter.Buch@dlr.de Project Management Agency of the German Aerospace Centre (PT-DLR) -Health Research-

Hungary	OTKA	http://www.otka.hu/	Béla Melegh University of Pécs Department of Medical Genetics Phone: +36-30-298-8711 (mobile) +36-72-536-427 (office) bela.melegh@aok.pte.hu
Israel	CSO-MOH	www.health.gov.il	Prof. Avi Israeli Phone: +972 25082156 avii@moh.health.gov.il
Italy	MoH	http://www.ministerosalute.it/	Dr. Gaetano Guglielmi Head Office 3 Health Research General Directorate for Health, Biomedical Research and Health Research Institutions Supervision. Ministry of Health Phone: +39 0659942186 g.guglielmi@sanita.it ; erare.italy@iss.it
Latvia	LAS	www.lza.lv	Uldis Berkis Centre of European Programs Latvian Academy of Sciences 1 Akademijas laukums, Riga, 1050 Latvia Tel: +371 67409242 uberkis@latnet.lv
Poland	NCBR	www.en.ncbir.pl/	Marcin Chmielewski National Centre for Research and Development. Poland (NCBR) phone: +48 22 39 07 109; marcin.chmielewski@ncbr.gov.pl
Portugal	FCT	www.fct.pt	Anabela Isidro Foundation for Science and Technology (FCT) Phone: +351 21 391 1552 Anabela.Isidro@fct.pt
Romania	UEFISCDI	http://uefiscdi.gov.ro/	Simona Cristina Stoian Executive Agency for Higher Education, Research, Development and Innovation Funding Phone: +40213023893 simona.stoian@uefiscdi.ro
Spain	ISCIII	www.isciii.es	Ignacio Baanante Phone: +34 9182 22576 era@isciii.es
Switzerland	SNSF	www.snf.ch	Claudia Rutte Division of Biology and Medicine Swiss National Science Foundation Phone +41(0)31 308 22 41 claudia.rutte@snf.ch

The Netherlands	ZonMw	www.zonmw.nl	<p>Sonja van Weely Phone: +31-(0)70 349 5220 (preferred): weely@zonmw.nl</p> <p>Harald Moonen Phone: +31-(0)70 349 53 49 moonen@zonmw.nl</p> <p>The Netherlands Organization for Health Research and Development (ZonMw)</p>
Turkey	TÜBİTAK	www.tubitak.gov.tr	<p>K. Melike SEVİMLİ Phone: +90- 312- 468 53 00 / 1976 ncphealth@tubitak.gov.tr</p> <p>A. Özge GÖZAY Phone: +90- 312- 468 53 00 / 1007 ncphealth@tubitak.gov.tr</p> <p>The Scientific and Technological Research Council of Turkey (TUBİTAK) EU Framework Programmes National Coordination Office</p>

ANNEX II. Indicative funding commitments of the participating organisations of the E-Rare-2 JTC 2014

Country/Region	Participating organisation	Envisioned amount of funding (M€ for 3 years)	Anticipated number of fundable research groups
Austria	Austrian Science Fund (FWF)	1	4
Belgium	Research Foundation - Flanders (FWO)	0.2	1
Canada	Canadian Institutes of Health Research Institute of Genetics(CIHR-IG) ¹	1.07	3-4
Canada	Fonds de recherche du Québec-Santé (FRQS) ²	0.36	1-2
France	French National Research Agency (ANR)	2	6-10
Germany	German Federal Ministry of Education and Research (BMBF)	3	10-15
Hungary	Hungarian Scientific Research Fund (OTKA)	0.15	2
Israel	Chief Scientist Office of the Ministry of Health (CSO-MOH) ³	0.24	4
Italy	Ministry of Health (MoH)	1	4-6
Latvia	Latvian Academy of Sciences (LAS)	0.4	2
Poland	National Centre for Research and Development (NCBiR)	0.5	2-3
Portugal	Foundation for Science and Technology (FCT)	0.2	1-2
Romania	Executive Agency for Higher Education, Research, Development & Innovation Funding (UEFISCDI)	0.5	1-6
Spain	National Institute of Health Carlos III (ISCIII)	0.2	2-3
Switzerland	Swiss National Science Foundation (SNSF) ⁴	0.82	5
The Netherlands	The Netherlands Organization for Health Research and Development (ZonMw)	1	4-6
Turkey	Scientific and Technological Research Council of Turkey (TÜBİTAK)	0.6	4-6

¹ CIHR-IG will fund to a maximum of \$1.5 million Canadian over three years (currently equivalent to 1.07 Mio €) to support operational research costs only. The Canadian amount will not be adjusted to reflect conversion rate changes.

² FRQS will fund to a maximum of \$0.5 million Canadian over three years (currently equivalent to 0.36 Mio €) to support operational research costs only. The Canadian amount will not be adjusted to reflect conversation rate changes. Funds are subject to availability of funds voted annually to FRQS by the National Assembly of Québec and FRQS Board of Directors' approval.

³ The CSO-MOH will fund up to 4 projects. The funding commitment is up to 240,000 €, depending on budget availability. Maximum funding per grant is 60,000 €.

⁴ SNSF has earmarked a budget of 1.0 million Swiss Francs over three years (currently equivalent to 0.82 Mio €).

ANNEX III. Eligibility of beneficiary institutions for the participating organisations of the E-Rare-2 JTC 2014

Country/Region	Institution	Eligible beneficiary Institution		
		Academia	Clinical/public health	Company
Austria	Austrian Science Fund (FWF)	Yes (3)	Yes (3)	Yes (3)
Belgium (Flanders)	Research Foundation - Flanders (FWO)	Yes	Yes (1,2)	No
Canada	Canadian Institutes of Health Research Institute of Genetics (CIHR-IG)	Yes	Yes	No
Canada (Québec)	Fonds de recherche du Québec-Santé (FRQS)	Yes	Yes	No
France	French National Research Agency (ANR)	Yes	Yes	Yes (1)
Germany	German Federal Ministry of Education and Research (BMBF)	Yes	Yes	Yes (1)
Hungary	Hungarian Scientific Research Fund (OTKA)	Yes	Yes	No
Israel	Chief Scientist Office of the Ministry of Health (CSO-MOH)	Yes	Yes	No
Italy	Ministry of Health (MoH) Italy	No	Yes (4)	No
Latvia	Latvian Academy of Sciences (LAS)	Yes	Yes	Yes (1)
Poland	National Centre for Research and Development (NCBR)	Yes	Yes	Yes
Portugal	Foundation for Science and Technology (FCT)	Yes	Yes	Yes (1)
Romania	Executive Agency for Higher Education, Research, Development & Innovation Funding (UEFISCDI)	Yes	Yes	Yes (1)
Spain	National Institute of Health Carlos III (ISCIII)	No	Yes	No
Switzerland	Swiss National Science Foundation (SNSF)	Yes (5)	Yes (5)	No
The Netherlands	The Netherlands Organization for Health Research and Development (ZonMw)	Yes (6)	Yes (6)	No (6)
Turkey	Scientific and Technological Research Council of Turkey (TÜBİTAK)	Yes	Yes	Yes (1)

Please note that the information on this table is only indicative

(1) The eligibility of companies and institutions is subjected to different conditions in each country/region. Further details regarding the eligible beneficiaries and other national eligibility criteria and requirements are available on the “guidelines for applicants” and the E-Rare-2 website (www.e-rare.eu).

(2) Only clinics associated with universities are eligible for the FWO.

(3) Applications for projects from Austria may only be submitted by single natural persons. Affirmation of the research institution (academia, clinical/public health, enterprise) of the applicant is mandatory.

(4) Research Hospital: Istituti di ricovero e cura a carattere scientifico (IRCCS). Only IRCCS (The Italian Scientific Institutes for Health Research and Health Care). The list of the IRCCS by Region and City is available here:

<http://www.salute.gov.it/ricercaSanitaria/paginaInternaMenuRicercaSanitaria.jsp?id=1064&menu=strumentieservizi>.

(5) SNSF eligibility check refers to formal and material criteria. Applicants must show that they have successfully carried out research work for several years, and must be capable of running a project under their sole responsibility and leading the project team engaged for the (sub) project. Proposals that are manifestly inadequate to be forwarded to external experts for review or show obvious substantial insufficiencies in any of the SNSF scientific assessment criteria are rejected and not forwarded to external review

(6) For universities, research institutes affiliated to universities, university medical centers, research hospitals and for health promoting institutes and knowledge institutes the several ZonMw grant terms and conditions (as of 1 July 2013) apply. Companies are not eligible for funding of ZonMw in this call, however co-financing by companies or in kind contribution of companies is encouraged.

Applicants are encouraged to contact their national/regional contact points for further information